Navigation Links
Angiotech and Symphony Medical Announce Licensing Agreement
Date:1/17/2008

New Clinical Program Under Development to Improve Outcomes of Coronary

Artery Bypass Grafting (CABG) and Cardiac Valve Surgeries

VANCOUVER, BC and LAGUNA HILLS, CA, Jan. 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) and privately held Symphony Medical, Inc. today announced that they have entered into an exclusive licensing agreement to employ one of Angiotech's proprietary PEG-based biomaterials as part of a prophylactic therapy envisioned to mitigate the onset of post-operative atrial fibrillation (POAF) for patients undergoing coronary artery bypass grafting and cardiac valve surgeries.

"This agreement is another example of our continuing effort to lessen the complications and improve the outcomes of patients living with cardiovascular disease," said Dr. Bill Hunter, President and CEO of Angiotech. "Our innovative use of cutting edge, site-specific therapy has been central to the development of coronary and peripheral drug-eluting stents, anti-restenosis therapy in bypass surgery and hemodialysis access procedures, and more recently, coronary stem cell therapy and treatments for arrhythmias following open heart surgery," added Dr. Hunter.

Symphony Medical has been engaged in the development of non-destructive biocompatible polymer therapies to treat significant cardiac conditions such as atrial fibrillation and congestive heart failure since 2003. Its lead program involves the development of a prophylactic injection of biopolymer to prevent or reduce the incidence of POAF that occur following coronary artery bypass grafting (CABG) and cardiac valve surgeries. The product under development is a kit which employs a biopolymer, applicator and specialized electrical stimu
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
(Date:7/25/2014)... AVIV, Israel , July 25, 2014  Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, today announced financial results ... First Half 2014 Financial Summary: , Reported cash ... 2014, compared with $137,000 at December 31, 2013.  ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... INTRODUCTION , ... encoded bacterial enzymes which hydrolyze β -lactam antibiotics. The majority of ... One successful approach to combating the serine active site β -lactamases ... in combination with a β -lactam antibiotic 4 . , There ...
... , Evelyn McGown and Michael Su , ... fluorogenic oligonucleotide probes developed by Kramerand associates to detect ... They are single-stranded oligonucleotides that exist in a ... which bind together to form a stem. Thestrained loop ...
... , Anne T. Ferguson, Ph.D., ... , , INTRODUCTION , This ... XS from Molecular Devices to study the performance of the LIVE/DEAD ... two fluorescent dyes, calcein AM (cal AM) and ethidium homodimer (EthD-1), ...
Cached Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 2Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 3Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 2LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 3LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 5
(Date:7/25/2014)... associate professor of biomedical engineering at the University ... tissue engineering and artificial organ development., "Introduction to ... guide to entering into the field of artificial ... of biomedical engineering at UH, served as a ... while there are other published books on the ...
(Date:7/25/2014)... opened the way for the development of new lines of ... barley production is second only to wheat with 7-8 million ... important diseases of barley. , Senior Research Scientist Dr Alan ... on the cell walls of barley plants that block the ... by the ARC Centre of Excellence in Plant Cell Walls ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... effort to make data storage more cost-effective, a group of ... Karlsruhe Institute of Technology in Germany have created a DNA-based ... (UV) light to make it possible to encode information. The ... Applied Physics Letters , consists of a thin film of ...
... Athens, Ga. The knowledge that bacteria possess adaptable immune ... invaders is relatively new to science, and researchers across the ... to apply that knowledge in industry and medicine. ... how to harness this bacterial immune system to selectively target ...
... Ore. - Newly published research by scientists at Oregon ... how early embryonic stem cells develop and take part ... took place at OHSU,s Oregon National Primate Research Center, ... chimeric monkeys -- monkeys developed from stem cells taken ...
Cached Biology News:UGA scientists 'hijack' bacterial immune system 2UGA scientists 'hijack' bacterial immune system 3OHSU research produces the world's first primate chimeric offspring 2
activating transcription factor 4 (tax-responsive enhancer element B67),...
Request Info...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
Biology Products: